AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Unconventional myosin-IXa

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

B2RTY4

UPID:

MYO9A_HUMAN

Alternative names:

Unconventional myosin-9a

Alternative UPACC:

B2RTY4; B0I1T5; C9IYB3; C9JA86; Q14787; Q3YLD7; Q3YLD8; Q6P986; Q9H8T5; Q9NTG2; Q9NUY2; Q9UEP3; Q9UNJ2

Background:

Unconventional myosin-IXa, also known as myosin-9a, is an actin-based motor molecule with ATPase activity, pivotal in intracellular movements. It plays a crucial role in regulating Rho by stimulating its GTPase activity in neurons, essential for neurite branching and motor neuron axon guidance.

Therapeutic significance:

Linked to Myasthenic syndrome, congenital, 24, presynaptic, unconventional myosin-IXa's understanding could pave the way for innovative therapeutic strategies targeting neuromuscular transmission disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.